HRMY
Harmony Biosciences Holdings, Inc.
September 29, 2026 · pre-market
- Rarity
- 1.92
- Peak move
- +9.89%
- Float cap
- $2.0B
Harmony Biosciences Holdings, Inc. is a neuroscience company focused on rare neurological diseases. It commercializes WAKIX (pitolisant), an FDA-approved oral treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy, and is developing therapies for idiopathic hypersomnia, Prader-Willi syndrome, rare epilepsies, and other central nervous system disorders.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingMizuho Securities maintained a Buy rating on Harmony Biosciences (HRMY) with a $51 price target on September 25, 2026.
analyst_ratingNeedham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences and raised the price target to $50, citing Phase 1 single-ascending-dose data showing a 25-hour half-life for the orexin-2 agonist BP-205.
analyst_ratingOppenheimer reiterated an Outperform rating and $70.00 price target on Harmony Biosciences (HRMY) on Sept 24, 2026, following the company's filing of a new patent infringement suit against generic rival AET invoking U.S. Patent No. 11,945,788 covering pitolisant manufacturing methods.